Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FTC, pharmacy benefit managers
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S.
Largest Pharmacy-Benefit Managers Hiked Up Drug Prices, FTC Says
The largest pharmacy-benefit managers hiked the prices of dozens of drugs dispensed through their own pharmacies, according to a new report by the Federal Trade Commission released on Tuesday.The markups helped the PBMs reap $7.
1d
on MSN
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
MedCity News
9h
Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
pharmaphorum
1d
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
6d
on MSN
Lawmakers urge FTC to release newest report on pharmacy benefit managers
A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an ...
policymed.com
1d
Second Federal Trade Commission Report on Pharmacy Benefit Managers (PBM’s) Focuses on Specialty Generics
The Federal Trade Commission (FTC) released its second interim staff report “Specialty Generic Drugs a Growing Profit Center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback